» Articles » PMID: 20624945

A Critical Role for IFN Regulatory Factor 1 in NKT Cell-mediated Liver Injury Induced by Alpha-galactosylceramide

Overview
Journal J Immunol
Date 2010 Jul 14
PMID 20624945
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

NKT cells are remarkably abundant in mouse liver. Compelling experimental evidence has suggested that NKT cells are involved in the pathogenesis of many liver diseases. Activation of NKT cells with alpha-galactosylceramide (alpha-GalCer) causes liver injury through mechanisms that are not well understood. We undertook studies to characterize the key pathways involved in alpha-GalCer-induced liver injury. We found that expression of the transcription factor IFN regulatory factor 1 (IRF-1) in mouse liver was dramatically upregulated by alpha-GalCer treatment. Neutralization of either TNF-alpha or IFN-gamma inhibited alpha-GalCer-mediated IRF-1 upregulation. alpha-GalCer-induced liver injury was significantly suppressed in IRF-1 knockout mice or in wild-type C56BL/6 mice that received a microRNA specifically targeting IRF-1. In contrast, overexpression of IRF-1 greatly potentiated alpha-GalCer-induced liver injury. alpha-GalCer injection also induced a marked increase in hepatic inducible NO synthase expression in C56BL/6 mice, but not in IRF-1 knockout mice. Inducible NO synthase knockout mice exhibited significantly reduced liver injury following alpha-GalCer treatment. Finally, we demonstrated that both NKT cells and hepatocytes expressed IRF-1 in response to alpha-GalCer. However, it appeared that the hepatocyte-derived IRF-1 was mainly responsible for alpha-GalCer-induced liver injury, based on the observation that inhibition of IRF-1 by RNA interference did not affect alpha-GalCer-induced NKT cell activation. Our findings revealed a novel mechanism of NKT cell-mediated liver injury in mice, which has implications in the development of human liver diseases.

Citing Articles

CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis.

Moorman C, Yu S, Briseno C, Phee H, Sahoo A, Ramrakhiani A Front Immunol. 2023; 14:1235222.

PMID: 37965348 PMC: 10641730. DOI: 10.3389/fimmu.2023.1235222.


C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease.

Fan Z, Sun X, Chen X, Liu H, Miao X, Guo Y JHEP Rep. 2023; 5(9):100805.

PMID: 37555008 PMC: 10404559. DOI: 10.1016/j.jhepr.2023.100805.


Metabolic Triggers of Invariant Natural Killer T-Cell Activation during Sterile Autoinflammatory Disease.

Riffelmacher T, Kronenberg M Crit Rev Immunol. 2021; 40(5):367-378.

PMID: 33463949 PMC: 7116673. DOI: 10.1615/CritRevImmunol.2020035158.


Acute invariant NKT cell activation triggers an immune response that drives prominent changes in iron homeostasis.

Huang H, Zuzarte-Luis V, Fragoso G, Calve A, Hoang T, Oliero M Sci Rep. 2020; 10(1):21026.

PMID: 33273556 PMC: 7713400. DOI: 10.1038/s41598-020-78037-3.


IL-23 mediates murine liver transplantation ischemia-reperfusion injury via IFN-γ/IRF-1 pathway.

Klune J, Bartels C, Luo J, Yokota S, Du Q, Geller D Am J Physiol Gastrointest Liver Physiol. 2018; 315(6):G991-G1002.

PMID: 30307739 PMC: 6336948. DOI: 10.1152/ajpgi.00231.2018.